Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted. Regulatory-affairs lead in a rare-disease team designing a pediatric plan has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this Pharmacovigilance extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for regulatory-affairs lead in a rare-disease team designing a pediatric plan. 4. Biosimilar analytical similarity report is missing the fact regulatory-affairs lead needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether biosimilar analytical similarity report supports the labeled claim regulatory-affairs lead would keep. 3. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for regulatory-affairs lead in a rare-disease team designing a pediatric plan.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for regulatory-affairs lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in biosimilar analytical similarity report that a second reviewer can re-perform